Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 3, Issue 8, pp. 1031-1039
PubMed
Published By
Print ISSN
Online ISSN
History
- May 26, 2004
- March 3, 2004
- May 12, 2004
- Published first August 6, 2004.
Copyright & Usage
American Association for Cancer Research
Author Information
- Mark A. Hull,
- Stanley C.W. Ko and
- Gillian Hawcroft
- Molecular Medicine Unit, University of Leeds, St. James's University Hospital, Leeds, United Kingdom
- Request for reprints: Mark A. Hull, Molecular Medicine Unit, University of Leeds, Clinical Sciences Building, St. James's University Hospital, Leeds LS9 7TF, United Kingdom. Phone: 44-113-206-5251; Fax: 44-113-242-9722. E-mail: M.A.Hull{at}leeds.ac.uk
August 2004
Volume 3, Issue 8
Volume 3, Issue 8
Prostaglandin EP receptors: Targets for treatment and prevention of colorectal cancer?
Jump to section
- Article
- Abstract
- The Prostaglandin Synthesis Pathway during Colorectal Carcinogenesis
- PGE2 Is the Predominant PG during Colorectal Carcinogenesis
- PGE2 Production by Human Colorectal Cancer Cells In vitro
- EP Receptors
- The Effect of PGE2 on Colorectal Epithelial Cells In vitro
- The Effect of PGE2 on Colorectal Epithelial Cell Proliferation and Intestinal Tumorigenesis In vivo
- Expression of Individual EP Receptor Isoforms in Normal Large Intestine and during Intestinal Tumorigenesis
- The Role of Individual EP Receptor Isoforms during Intestinal Tumorigenesis
- Therapeutic Implications of EP Receptor Signaling for Treatment of GI Cancer
- Summary
- Footnotes
- References
- Figures & Data
- Info & Metrics
Advertisement